YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Earnings Call Insights: Atea Pharmaceuticals (AVIR) Q2 2026 MANAGEMENT VIEW * "The positive top line results from C-BEYOND, our Phase III trial evaluating the combination of bemnifosbuvir for the treatment of hepatitis C in North America r…
BOSTON, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious vira…
Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Atea Pharmaceuticals Inc. announced on Tuesday positive topline findings from its pivotal North American Phase 3 C-BEYOND clinical trial e…
Atea Pharmaceuticals (AVIR) said Tuesday a pivotal phase 3 trial of its experimental combination the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
On February 2, BML Capital Management, LLC disclosed a new position in CarMax(NYSE:KMX), acquiring 155,000 shares in an estimated $5.99 million trade based on quarterly average pricing. What happened According to an SEC filing dated Februa…
On February 2, BML Capital Management disclosed in a Securities and Exchange Commission filing that it sold out of Alumis(NASDAQ:ALMS), liquidating 1,210,415 shares in an estimated $4.83 million trade. What happened According to a Securiti…
Atea Pharmaceuticals, Inc. Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outsid…
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral dis…
(RTTNews) - Atea Pharmaceuticals Inc. (AVIR) has completed patient enrolment in its pivotal North American Phase 3 trial, dubbed C-BEYOND, evaluating the fixed-dose combination of Bemnifosbuvir and Ruzasvir for the treatment of hepatitis C…
Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expe…
As the U.S. stock market experiences a pullback, with major indices like the Dow Jones and S&P 500 facing consecutive losses amid tech sector concerns, investors are increasingly looking for opportunities outside the mainstream. Penny stoc…
By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapie…
BOSTON, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral dis…
As the Dow Jones Industrial Average reaches new heights, closing above 48,000 for the first time amid optimism about an end to the U.S. government shutdown, investors are keenly observing market dynamics that may influence their portfolios…
Earnings Call Insights: Atea Pharmaceuticals (AVIR) Q3 2025 MANAGEMENT VIEW * CEO Jean-Pierre Sommadossi reported "significant progress and achievements" this quarter, highlighting the advancement of Atea's global Phase III program for HCV…
BOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral dis…
BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral dis…
As the major U.S. stock indices recently reached new highs, only to retreat slightly, investors are keenly observing market dynamics and seeking opportunities that align with current economic conditions. Among these opportunities are penny…
Introduction & Market Context Atea Pharmaceuticals (NASDAQ:AVIR) presented its Q2 2025 corporate update on August 7, highlighting significant progress in its hepatitis C virus (HCV) treatment program and providing insights into its financi…
Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response…
BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral dis…
The market has been flat over the last week, but is up 18% over the past year, with earnings forecast to grow by 15% annually. For investors willing to explore beyond well-known stocks, penny stocks—often smaller or newer companies—can off…
Over the last 7 days, the U.S. market has risen by 1.7%, and over the past year, it is up 12%, with earnings forecasted to grow by 15% annually. In light of these conditions, identifying stocks that offer both value and growth potential be…
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration,…
Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented…
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral di…
BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious vira…
Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk for Drug-Drug Interactions and Convenience with No Food Effect HCV Infection Remains a Significant Global Health Burden, with Approximately 50 Million Peop…
BOSTON, March 26, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral di…
BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral dis…
BOSTON, March 19, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral di…
Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, March 06,…
BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to…
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral dis…
Atea Pharmaceuticals, Inc. AVIR, a clinical-stage company, reported positive initial data from the first 52 patients in the lead-in cohort of the mid-stage study evaluating its bemnifosbuvir and ruzasvir (RZR) combination therapy for the t…
Atea Pharmaceuticals, Inc. A 98% Sustained Virologic Response at Week 4 (SVR4) Post-Treatment Observed in Initial Data From 52 Patients in Lead-In Cohort in Phase 2 HCV Study Phase 3 SUNRISE-3 Enrollment Surpassed 650 Patients in Monothera…